Challenges in validating candidate therapeutic targets in cancer

More than 30 published articles have suggested that a protein kinase called MELK is an attractive therapeutic target in human cancer, but three recent reports describe compelling evidence that it is not. These reports highlight the caveats associated with some of the research tools that are commonly...

Descripción completa

Detalles Bibliográficos
Autores principales: Settleman, Jeffrey, Sawyers, Charles L, Hunter, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2018
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805407/
https://www.ncbi.nlm.nih.gov/pubmed/29417929
http://dx.doi.org/10.7554/eLife.32402
_version_ 1783298967920967680
author Settleman, Jeffrey
Sawyers, Charles L
Hunter, Tony
author_facet Settleman, Jeffrey
Sawyers, Charles L
Hunter, Tony
author_sort Settleman, Jeffrey
collection PubMed
description More than 30 published articles have suggested that a protein kinase called MELK is an attractive therapeutic target in human cancer, but three recent reports describe compelling evidence that it is not. These reports highlight the caveats associated with some of the research tools that are commonly used to validate candidate therapeutic targets in cancer research.
format Online
Article
Text
id pubmed-5805407
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-58054072018-02-12 Challenges in validating candidate therapeutic targets in cancer Settleman, Jeffrey Sawyers, Charles L Hunter, Tony eLife Cancer Biology More than 30 published articles have suggested that a protein kinase called MELK is an attractive therapeutic target in human cancer, but three recent reports describe compelling evidence that it is not. These reports highlight the caveats associated with some of the research tools that are commonly used to validate candidate therapeutic targets in cancer research. eLife Sciences Publications, Ltd 2018-02-08 /pmc/articles/PMC5805407/ /pubmed/29417929 http://dx.doi.org/10.7554/eLife.32402 Text en © 2018, Settleman et al http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Cancer Biology
Settleman, Jeffrey
Sawyers, Charles L
Hunter, Tony
Challenges in validating candidate therapeutic targets in cancer
title Challenges in validating candidate therapeutic targets in cancer
title_full Challenges in validating candidate therapeutic targets in cancer
title_fullStr Challenges in validating candidate therapeutic targets in cancer
title_full_unstemmed Challenges in validating candidate therapeutic targets in cancer
title_short Challenges in validating candidate therapeutic targets in cancer
title_sort challenges in validating candidate therapeutic targets in cancer
topic Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805407/
https://www.ncbi.nlm.nih.gov/pubmed/29417929
http://dx.doi.org/10.7554/eLife.32402
work_keys_str_mv AT settlemanjeffrey challengesinvalidatingcandidatetherapeutictargetsincancer
AT sawyerscharlesl challengesinvalidatingcandidatetherapeutictargetsincancer
AT huntertony challengesinvalidatingcandidatetherapeutictargetsincancer

Ejemplares similares